Annual Accounts Payable
$13.37 M
-$1.79 M-11.84%
December 31, 2024
Summary
- As of February 22, 2025, RPRX annual accounts payable is $13.37 million, with the most recent change of -$1.79 million (-11.84%) on December 31, 2024.
- During the last 3 years, RPRX annual accounts payable has risen by +$7.75 million (+137.90%).
- RPRX annual accounts payable is now -11.84% below its all-time high of $15.16 million, reached on December 31, 2023.
Performance
RPRX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$13.37 M
-$8.69 M-39.38%
December 31, 2024
Summary
- As of February 22, 2025, RPRX quarterly accounts payable is $13.37 million, with the most recent change of -$8.69 million (-39.38%) on December 31, 2024.
- Over the past year, RPRX quarterly accounts payable has dropped by -$1.79 million (-11.84%).
- RPRX quarterly accounts payable is now -61.10% below its all-time high of $34.37 million, reached on June 30, 2020.
Performance
RPRX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
RPRX Accounts Payable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -11.8% | -11.8% |
3 y3 years | +137.9% | -11.8% |
5 y5 years | +19.6% | -11.8% |
RPRX Accounts Payable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -11.8% | +137.9% | -42.9% | +137.9% |
5 y | 5-year | -11.8% | +137.9% | -61.1% | +137.9% |
alltime | all time | -11.8% | +198.6% | -61.1% | +137.9% |
Royalty Pharma Accounts Payable History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $13.37 M(-11.8%) | $13.37 M(-39.4%) |
Sep 2024 | - | $22.05 M(-5.8%) |
Jun 2024 | - | $23.42 M(+102.7%) |
Mar 2024 | - | $11.55 M(-23.8%) |
Dec 2023 | $15.16 M(+91.8%) | $15.16 M(+11.3%) |
Sep 2023 | - | $13.63 M(+134.6%) |
Jun 2023 | - | $5.81 M(-12.7%) |
Mar 2023 | - | $6.66 M(-15.8%) |
Dec 2022 | $7.91 M | $7.91 M(-50.9%) |
Sep 2022 | - | $16.11 M(+32.3%) |
Jun 2022 | - | $12.18 M(+82.8%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2022 | - | $6.66 M(+18.5%) |
Dec 2021 | $5.62 M(-47.8%) | $5.62 M(-38.8%) |
Sep 2021 | - | $9.19 M(-2.2%) |
Jun 2021 | - | $9.39 M(+13.6%) |
Mar 2021 | - | $8.27 M(-23.2%) |
Dec 2020 | $10.78 M(-3.6%) | $10.78 M(-55.8%) |
Sep 2020 | - | $24.39 M(-29.0%) |
Jun 2020 | - | $34.37 M(+65.6%) |
Mar 2020 | - | $20.75 M(+85.7%) |
Dec 2019 | $11.18 M(+149.7%) | $11.18 M |
Dec 2018 | $4.48 M | - |
FAQ
- What is Royalty Pharma annual accounts payable?
- What is the all time high annual accounts payable for Royalty Pharma?
- What is Royalty Pharma annual accounts payable year-on-year change?
- What is Royalty Pharma quarterly accounts payable?
- What is the all time high quarterly accounts payable for Royalty Pharma?
- What is Royalty Pharma quarterly accounts payable year-on-year change?
What is Royalty Pharma annual accounts payable?
The current annual accounts payable of RPRX is $13.37 M
What is the all time high annual accounts payable for Royalty Pharma?
Royalty Pharma all-time high annual accounts payable is $15.16 M
What is Royalty Pharma annual accounts payable year-on-year change?
Over the past year, RPRX annual accounts payable has changed by -$1.79 M (-11.84%)
What is Royalty Pharma quarterly accounts payable?
The current quarterly accounts payable of RPRX is $13.37 M
What is the all time high quarterly accounts payable for Royalty Pharma?
Royalty Pharma all-time high quarterly accounts payable is $34.37 M
What is Royalty Pharma quarterly accounts payable year-on-year change?
Over the past year, RPRX quarterly accounts payable has changed by -$1.79 M (-11.84%)